Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04579666 · ClinicalTrials.gov registry record · Phase 2
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Apellis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT04579666 is a Phase 2 study that was terminated before completion, run by Apellis Pharmaceuticals. The registered enrollment target is 249 participants.
The verdict
NCT04579666, a Phase 2 study, was terminated before completion, sponsored by Apellis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Interventions
- OTHER Placebo
- DRUG Pegcetacoplan (APL-2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2023-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04579666
The ClinicalTrials.gov registry entry for NCT04579666 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04579666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04579666 about?
NCT04579666 is a clinical study titled "MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)". This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
What is the current status of trial NCT04579666?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2020-09-30. Estimated completion is 2023-07-13.
What interventions are being tested in trial NCT04579666?
The interventions under investigation include: Placebo (OTHER), Pegcetacoplan (APL-2) (DRUG).
Who is sponsoring clinical trial NCT04579666?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.